A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130850 in Participants With Advanced Solid and Hematologic Tumors

NCT06188208 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

132

Enrollment

INDUSTRY

Sponsor class

Stopped The study has ended

Conditions

Advanced Solid Tumors
Advanced Hematologic Tumors

Interventions

DRUG: VVD-130850
DRUG: Pembrolizumab

Sponsor

Vividion Therapeutics, Inc.